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Identity 
Other names: CD135; FLK2 (Fetal liver kinase 2); 
STK1 (Stem cell kinase 1) 




The FLT3 gene contains 24 exons and spans 96,982 
bases (start: 27,475,753 bp to end 27,572,735 from 
13pter) oriented at the minus strand. 
Transcription 
3.7 kb; 2979 bp open reading frame. 
Protein 
Description 
Size: 993 amino acids; 112804 Da; FLT3 is a class III 
receptor tyrosine kinase (RTK) structurally related to 
the receptors for platelet derived growth factor (PDGF), 
colony stimulating factor 1 (CSF1), and KIT ligand 
(KL).; these RTK contain five immunoglobulin-like 
domains in the extracellular region and an intracelular 
tyrosine kinase domain splitted in two by a specific 
hydrophilic insertion (kinase insert); 
immunoprecipitation of the human FLT3 protein results 
in the appearance of a minor band of Mr 130 000 and a 
major band of Mr 155 000/160 000; the high-
molecular-weight band corresponds to the mature, N-
glycosylated form, and the low-molecular-weight band 




linked glycosylations account for 50 000 daltons. 
Expression 
FLT3 expression was described on bone marrow 
CD34-positive cells, corresponding to multipotential, 
myeloid and B-lymphoid progenitor cells, and on 
monocytic cells; FLT3 expression is restricted to cells 
of the fetal liver expressing high levels of CD34; in 
addition, the FLT3 protein is expressed on blast cells 
from most ANLL and B-ALL. 
Localisation 
Subcellular location: Type I membrane protein. 3D 
structure: PDB id 1RJB (3D). 
Function 
FLT3 receptor function can be defined by the activity 
of its ligand (FL); FL is an early acting factor and 
supports the survival, proliferation and differentiation 
of primitive hemopoietic progenitor cells. Ligand 
binding to FLT3 promotes receptor dimerization and 
subsequent signalling through posphorylation of 
multiple cytoplasmatic proteins, including SHC, SHP-
2, SHIP, Cbl, Cbl-b, Gab1 and Gab2, as well as the 
activation of several downstream signalling pathways, 
such as the Ras/Raf/MAPK and PI3 kinase cascades. 
Function: Receptor for the FL cytokine. Has a tyrosine-
protein kinase activity. Catalytic activity: ATP + a 
protein tyrosine = ADP + protein tyrosine phosphate. 
Similarity: Belongs to the Tyr protein kinase family. 
CSF-1/PDGF receptor subfamily. Contains 1 
immunoglobulin-like C2-type domain. 
Homology 















Mutations in the FLT3 gene are the most frequent 
genetic aberration that have been described in acute 
myeloid leukemia. With 20-25% length mutations in 
the juxtamembrane domain are the most frequent, 
followed by 7-8% mutations in the second tyrosine 
kinase kinase domain, mostly point mutations in codon 
835 or deletions of codon 836. Also point mutations in 
the juxta membrane domain have been described and 
the number of new mutations all over the total gene is 
still growing. 
Implicated in 
FLT3-length mutation (FLT3-LM) 
Disease 
Internal tandem duplications and/or insertions and, 
rarely, deletions in the FLT3-gene are implicated in 20-
25% of all acute myeloid leukemias (AML). It was also 
described to be involved in 5-10 % myelodysplastic 
syndromes (MDS) refractory anaemia with excess of 
blasts (RAEB 1 and RAEB 2) and rare cases with acute 
lymphoblastic leukemia (ALL) The duplicated 
sequence belongs to exon 11 but sometimes involves 
intron 11 and exon 12. The most frequently used 
nomenclature is FLT3-ITD (internal tandem 
duplication). Because of the very heterogenous 
molecular structure the term FLT3-LM (length 
mutation) seems to be more adequate. 
Prognosis 
An unfavourable impact on prognosis especially a high 
relapse rate of the FLT3-LM has been shown by many 
study groups. Patients with loss of the wildtype allele 
have an even worse prognosis than the mutated with 
retention of the wildtype allele. Perspective: It is of 
special interest that this mutation allows to perform 
PCR-based minimal residual disease detection in a high 
number of these high risk AML patients. 
Cytogenetics 
FLT3-LM are highly correlated with a) normal 
karyotype, b) t(15;17)(q25;q21) c) Perspective: It is of 
special interest that this mutation allows to perform 
PCR-based minimal residual disease detection in a high 
number of these high risk AML patients. 
Oncogenesis 
This mutation leads to constitutive ligand independent 
autophosphorylation of the receptor. The FLT3-LM 
vary in size and position in a nearly patient specific 
manner. Overall the aberrant structure of the 
juxtamembrane domain disrupts a  
negative regulatory domain, which leads to the 
constitutive receptor activation. Several Groups have 
reported qualitative differences in the intracellular  
signals provided by wild type and mutated 
receptors.Mutated receptor weakly works through MAP 
kinase and Akt but instead through strong and 
constitutively activated STAT5. 
FLT3 Tyrosine Kinase Domain Mutation 
(FLT3-TKD) 
Disease 
In the second tyrosine kinase domain point mutations 
and small deletions mostly of codons 835 and 836, 
respectively, can be found in 7-8% of all AML. 
Prognosis 
No independent impact on prognosis shown yet. 
Cytogenetics 
In contrast to the FLT3-LM they do not seem to be 
specifically correlated to a certain AML type. 
Oncogenesis 
These mutations also lead to constitutive autoactivation 
of the receptor. It has been suggested that TKD 
mutation may both trigger the activation loop and 
stabilize it in the active state. 
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